FINWIRES · TerminalLIVE
FINWIRES

ASX:CSL

24 stories mentioning ASX:CSLUpdated 1d ago

Every FINWIRES story that references ASX:CSL, newest first.

Asia

Australian Shares Advance; Rio Tinto Group Posts Higher H1 Underlying Earnings, Revenue

Australian shares advanced further on Wednesday, as investors reacted to softer-than-expected June quarter inflation data, cutting expectations of a rate hike.The S&P/ASX 200 Index gained 1.01%, or 90.80 points, to close at 9,038.60, setting a new 100-day high.Brent crude oil futures rose to trade around $86 per barrel after the US military said Iran launched multiple ballistic missiles, which had been intercepted.Overnight on Wall Street, the Dow Jones Industrial Average rose 1% and the S&P 500 inched up 0.2%, while the Nasdaq Composite fell 0.2%.On the domestic front, Australia's consumer price index rose 3.8% in the 12 months to June from a 4% increase in the year to May. Trimmed mean annual inflation was 3.6% in the 12 months to June, unchanged from the 12 months to May.In company news, Rio Tinto Group (ASX:RIO) reported Wednesday that its underlying earnings per basic share in the first half rose to $4.214, from $2.96 a year earlier. Consolidated sales revenue for the six months ended June 30 was $31.03 billion, up from $26.87 billion in the same period last year.Woodside Energy Group (ASX:WDS) reported second-quarter operating revenue of $4.19 billion, up 28% from $3.28 billion a year earlier. The company's quarterly production volume hit 41.3 million barrels of oil equivalent (MMboe), down 18% from 50.1 MMboe in the year-ago period.Lastly, CSL (ASX:CSL) is set to conduct clinical trial work to confirm the efficacy and safety of immunoglobulin manufactured using its Horizon 2 process. It expects clinical activities to start in mid-2027.

ASX 200ASX:CSLASX:RIOASX:WDS
Asia

ASX Midday Sector Update: Healthcare Stocks Lead Broad-Based Rally

Healthcare stocks jumped nearly 4%, leading a broad-based rally at midday Wednesday.CSL (ASX:CSL) gained almost 7% in recent trade following news that it will conduct clinical trial work to confirm the efficacy and safety of immunoglobulin manufactured using its Horizon 2 process.Meanwhile, the financial sector edged up nearly 1%.Commonwealth Bank (ASX:CBA) shares inched up in recent trade.

ASX 200ASX:CBAASX:CSL
Asia

CSL to Conduct Trial Work to Confirm Efficacy, Safety of Immunoglobulin Produced Via Proprietary Process; Shares Jump 6%

CSL (ASX:CSL) will conduct clinical trial work to confirm the efficacy and safety of immunoglobulin manufactured using its Horizon 2 process, according to a Wednesday Australian bourse filing.The company said it expects clinical activities to start in mid-2027.The process enables greater production of immunoglobulin from the same base amount of plasma, per the filing.The company said it will obtain clinical evidence to support and finalize regulatory approval processes for Horizon 2 after its engagements with the US Food and Drug Administration and European Medicines Agency.CSL's shares rose nearly 6% in recent trading on Wednesday.

ASX:CSL
Asia

CSL Says Topline Phase 3b Results Support Plan to Seek Expanded Pediatric Indication for Andembry

CSL's (ASX:CSL) Andembry drug showed a favorable safety and tolerability profile in a phase 3b study in children aged between two and 11 years with hereditary angioedema, a genetic disorder characterized by severe swelling, according to a late Monday statement.The company said it observed treatment response across the study population, with most of the participants remaining attack-free during the 12-month treatment period.The topline results support CSL's plan to seek an expanded pediatric indication for Andembry, and the company intends to start submitting filings to health authorities in the first half of its fiscal year.CSL shares gained 1% in recent Tuesday trade.

ASX:CSL
Asia

ASX Midday Sector Update: Materials Stocks Jump, Healthcare Sector Struggles

Materials stocks advanced nearly 3% at midday Wednesday.BHP Group (ASX:BHP) gained more than 3% in recent trade.On the flip side, the healthcare sector struggled, shedding 2%.CSL (ASX:CSL) shares fell 3% in recent trade.

ASX 200ASX:BHPASX:CSL
Asia

ASX Midday Sector Update: Information Technology Stocks Inch Up, Healthcare Sector Struggles

Information technology stocks advanced 1.3% at midday Tuesday.Xero (ASX:XRO) shares rose marginally in recent trade.Meanwhile, the healthcare sector struggled, shedding nearly 1.4%.CSL (ASX:CSL) shares fell past 1% in recent trade.

ASX 200ASX:CSLASX:XRO
Asia

ASX Midday Sector Update: Healthcare Stocks Advance, Consumer Staples Sector Struggles

Healthcare stocks advanced over 1% at midday Wednesday.CSL (ASX:CSL) gained nearly 3% in recent trade.Meanwhile, the consumer staples sector struggled, shedding nearly 3%.Woolworths Group (ASX:WOW) shares fell past 2% in recent trade.

ASX 200ASX:CSLASX:WOW
Asia

CSL Says CHMP Recommends Revocation of TAVNEOS Marketing Authorization in Europe

CSL (ASX:CSL) said the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued an opinion recommending the revocation of the European Union marketing authorization for TAVNEOS, following a review of the handling of data in the Phase 3 ADVOCATE clinical trial supporting the product's approval, according to a Monday Australian bourse filing.The company said it expects to stop new patient initiation in the EU and European Economic Area (EEA) markets pending the European Commission decision, consistent with regulatory guidance."While we are disappointed in the outcome of the Article 20 procedure, we will respect the regulatory process and are committed to implementing it in full," said Bill Mezzanotte, CSL's head of research & development.TAVNEOS, an in-licensed therapy sold by CSL Vifor affiliates under license in the EU and EEA markets for the treatment of patients with severe, active anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis in combination with standard therapies, the filing added.

ASX:CSL
Asia

CSL, Plasma Industry Could Continue to Grow Strongly for Considerable Period, Jefferies Says

CSL (ASX:CSL) and the plasma industry could continue to grow strongly for a considerable period, Jefferies said in a Thursday note.The plasma industry is treating at most 34% of the total potential patients that it could in the US and European Union markets. CSL's immunoglobulin franchise accounts for 38% of its fiscal year 2026 group revenue estimate of AU$15.11 billion.Despite potential competitor entry into the autoimmune myositis market, any potential future competitor approvals in dermatomyositis and immune-mediated necrotizing myopathy are not seen as having a material effect on immunoglobulin volumes.Immunoglobulin is considered a second-line therapy in autoimmune myositis. 4% of the volume of immunoglobulin used in Australia is for autoimmune myositis, according to the Australian National Blood Authority data.The investment firm has a hold rating on CSL and a price target of AU$108 per share.

ASX:CSL
Asia

ASX Midday Sector Update: Healthcare Stocks Jump, Materials Sector Struggles

Healthcare stocks advanced nearly 3% at midday Thursday.CSL (ASX:CSL) gained almost 3% in recent trade.Meanwhile, the materials sector struggled, shedding more than 2%.BHP Group (ASX:BHP) shares fell nearly 2% in recent trade.

ASX 200ASX:BHPASX:CSL
Asia

ASX Midday Sector Update: Healthcare Stocks Inch Up, Materials Sector Struggles

Healthcare stocks advanced almost 1% at midday Tuesday.CSL (ASX:CSL) gained 2% in recent trade.Meanwhile, the materials sector struggled, shedding nearly 1%.BHP Group (ASX:BHP) shares fell marginally in recent trade.

ASX 200ASX:BHPASX:CSL
Japan

ASX Midday Sector Update: Healthcare Stocks Rise, Materials Sector Struggles

Healthcare stocks rose 1% at midday Friday.CSL (ASX:CSL) gained nearly 3% in recent trade.On the flip side, the materials sector struggled, shedding 3%.BHP Group (ASX:BHP) shares were down nearly 4% in recent trade after increasing the estimated investment for its Jansen stage two potash project to $6.9 billion from $4.9 billion following a cost and schedule review.

ASX 200ASX:BHPASX:CSL
Asia

CSL Unit Signs Five-Year Lease Contract with Clever Culture Systems for APAS Independence Instrument

CSL's (ASX:CSL) CSL Behring subsidiary signed a five-year contract with Clever Culture Systems (ASX:CC5) for the lease of an APAS Independence instrument and environmental monitoring analysis modules, according to a Tuesday filing with the Australian bourse.APAS Independence is an instrument that automates the imaging, interpretation, and reporting of microbial growth on culture plate media for labs.The contract will be paid in monthly installments, with an initial minimum non-cancellable period of six months following the start of the company's formal validation, which must occur on or before Dec. 31, the filing said.CSL shares rose 1% in morning trade on Tuesday, while Clever Culture Systems shares were up 5%.

ASX:CC5ASX:CSL
Asia

ASX Midday Sector Update: Healthcare Stocks Jump, Materials Sector Struggles

Healthcare stocks jumped nearly 3% at midday Friday.CSL (ASX:CSL) gained 4% in recent trade.Meanwhile, the materials sector struggled, shedding nearly 2%.BHP Group (ASX:BHP) shares fell nearly 2% in recent trade.

ASX 200ASX:BHPASX:CSL
Asia

ASX Midday Sector Update: Information Technology Stocks Jump, Healthcare Sector Falls

Information technology stocks advanced more than 5% at midday Monday.Xero (ASX:XRO) gained 8% in recent trade.On the flip side, the healthcare sector struggled, shedding nearly 2%.CSL (ASX:CSL) shares fell almost 2% in recent trade.

ASX 200ASX:CSLASX:XRO
Asia

ASX Biggest Losers

Here are the ASX-listed companies with the biggest losses on Friday.Energy Resources of Australia (ASX:ERA): -20%, AU$0.002Champion Iron (ASX:CIA): -5%, AU$4.54Superloop (ASX:SLC): -5%, AU$3.42Weebit Nano (ASX:WBT): -4%, AU$7.05Helia Group (ASX:HLI): -3%, AU$4.84GemLife Communities Group (ASX:GLF): -3%, AU$4.45Karoon Energy (ASX:KAR): -3%, AU$1.94Viva Energy Group (ASX:VEA): -2%, AU$2.11Ryman Healthcare (ASX:RYM): -2%, AU$1.88CSL (ASX:CSL): -2%, AU$96.05

ASX 200ASX:CIAASX:CSLASX:ERAASX:GLFASX:HLIASX:KARASX:RYMASX:SLCASX:VEAASX:WBT
Asia

CSL Says CEO Indirectly Acquires Nearly AU$108,000 Worth of Shares

CSL (ASX:CSL) said Chief Executive Gordon Naylor indirectly acquired 1,100 CSL ordinary shares in an on-market purchase on Wednesday for a consideration of AU$107,800, according to a Thursday Australian bourse filing.Naylor-Stewart Investments, as trustee for the Naylor-Stewart Family Trust, holds the shares.CLS's shares fell almost 2% in recent trading on Thursday.

ASX:CSL
Asia

CSL Enters Agreement to Boost Influenza Pandemic Preparedness in Latin America, Caribbean

CSL (ASX:CSL) signed a multi-year agreement with the Pan American Health Organization to boost preparedness for potential influenza pandemics in Latin America and the Caribbean, according to a Wednesday statement.Under the deal, CSL Seqirus has reserved "millions" of vaccine doses that participating countries across the region can order if an influenza pandemic is declared, the company said.CSL Seqirus will collaborate with Argentine production partner Sinergium Biotech to ensure rapid manufacturing and delivery of the vaccines if required.CSL shares advanced 1% in recent Wednesday trade.

ASX:CSL
Asia

CSL's Fiscal-Year Earnings Guidance Downgrade Not Surprising, Jefferies Says

CSL's (ASX:CSL) fiscal-year earnings guidance downgrade was not surprising with the documented issues in immunoglobulin in the US and albumin in China, Jefferies said in a Monday note.The biotechnology company now expects fiscal-year revenue of around $15.2 billion and net profit after tax adjusted to exclude amortization of around $3.1 billion, both on a constant-currency basis.The revision is mainly due to a $300 million hit from excess immunoglobulin inventory in US hospitals and a $200 million shortfall from aggressive albumin price competition in China.However, Jefferies believes that both markets remain underpenetrated, indicating potential growth for the industry in the medium term.Following the downgrade, Jefferies wants to see if the company can provide a clear profit growth outlook for fiscal years 2027 and 2028.The firm maintained its buy rating on CSL and lowered its price target to AU$195 from AU$212.CSL shares fell 2% in midday trade on Tuesday and earlier hit their lowest since October 2015.

ASX:CSL
Asia Markets

Australian Shares Retreat; CSL Cuts Fiscal Year 2026 Outlook, Flags $5 Billion of Additional Impairments

Australian shares retreated on Monday amid reports that the process to reach a peace agreement between Iran and the US had stalled over the weekend.The S&P/ASX 200 Index fell 0.49%, or 42.60 points, to close at 8,701.80.Brent crude oil futures rose over 4% to trade around $105 per barrel after the US rejected Iran's response to a US proposal to end the conflict and reopen shipping through the Strait of Hormuz.On the domestic front, the total number of dwellings approved in Australia fell around 11% to 17,300 in March, seasonally adjusted, from 19,339 in the previous month, according to final figures released by the Australian Bureau of Statistics.In company news, CSL (ASX:CSL) lowered its guidance for fiscal 2026 and expects to recognize about $5 billion of additional non-cash, pre-tax impairments across fiscal 2026 and 2027 beyond those the company disclosed earlier this year.The biotechnology company now expects fiscal 2026 revenue of around $15.2 billion and net profit after tax adjusted to exclude amortization of around $3.1 billion, both on a constant-currency basis. Its shares closed down 15%, earlier hitting their lowest since December 2016.Dyno Nobel (ASX:DNL) reported fiscal first-half earnings of AU$0.089 per share, excluding individually material items, up from AU$0.046 a year earlier. Revenue from ordinary activities for the six months ended March 31 was AU$1.9 billion, compared with AU$2.25 billion a year earlier. It shares rose 7% on close after earlier hitting their highest since January 2023.Lastly, Inghams Group (ASX:ING) reaffirmed its fiscal 2026 guidance for underlying earnings before interest, taxes, depreciation, and amortization of AU$180 million to AU$200 million. Its shares jumped 7% on market close.

ASX 200ASX:CSLASX:DNLASX:ING

Showing 1-20 of 24

Track with the FINWIRES app suite

FolioX
FolioX
Track ASX:CSL in your portfolio
WheelAI
WheelAI
Analyze ASX:CSL options with the wheel strategy
StockInsider
StockInsider
See market sentiment on ASX:CSL